Login to Your Account

Quest a Surprise Winner

Merck Terminates Odanacatib Trial Early on Positive Results

By Catherine Shaffer
Staff Writer

Friday, July 13, 2012

Some investors were puzzled when shares of Quest Diagnostics Inc. surged nearly 5 percent Thursday morning for apparently no reason. They could hardly be blamed for not knowing that Madison, N.J.-based Quest is entitled to a rather large payday upon commercialization of Merck & Co. Inc.'s odanacatib, which just blasted through its Phase III study goals upon interim analysis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription